Neuren Pharmaceuticals Limited (NURPF)

USD 8.22

(0.0%)

Market Cap (In USD)

1.05 Billion

Revenue (In USD)

231.94 Million

Net Income (In USD)

157.08 Million

Avg. Volume

525.00

Currency
USD
Country
Healthcare
Open
-
Prev. Close
-
Day Range
-
Year Range
6.61-17.205
PE
-
EPS
-
Beta Value
2.174
ISIN
NZNEUE0001S8
CUSIP
-
CIK
-
Shares
-
Earnings Annoncement
-

Company Profile

Sector
Healthcare
Industry
Biotechnology
CEO
Mr. Jonathan Charles Pilcher A.C.A., ACA, B.Sc., BSc (Hons), F.C.A.
Employee Count
-
Website
https://www.neurenpharma.com
Ipo Date
2009-11-04
Details
Neuren Pharmaceuticals Limited, a biopharmaceutical company, develops drugs for the treatment of neurological disorders. Its lead product is trofinetide, which is in Phase III clinical trial for the treatment of Rett syndrome, as well as has completed Phase II clinical trial to treat Fragile X syndrome. The company also develops NNZ-2591, which has completed Phase I clinical trial for the treatment of Phelan-McDermid, Angelman, Pitt Hopkins, and Prader-Will syndromes. In addition, it provides development services; and holds loan funded shares. The company was incorporated in 2001 and is based in Camberwell, Australia.